article thumbnail

Barriers are limiting UK childhood vaccination, say doctors

pharmaphorum

The Vaccination in the UK: Access, uptake and equity (PDF) report notes that, over the last decade, the uptake of vaccines in the UK has stalled and is in many cases falling, leading to outbreaks of preventable diseases such as measles and whooping cough.

article thumbnail

Does the pandemic mark a turning point in vaccine development?

pharmaphorum

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ACIP backs block on flu vaccines with thimerosal additive

pharmaphorum

The CDCs newly constituted Advisory Committee on Immunization Practices (ACIP) has voted to recommend the removal of vaccine preservative, thimerosal, that has become a focal point for activists trying to link vaccines to autism. Of all the issues the ACIP needs to focus on, this is not a big issue. The American people deserve no less."

article thumbnail

Building agile partner relationships at a vaccine-focused biotech

pharmaphorum

In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health. Jeff Baxter – President and CEO, VBI Vaccines. Mr. Baxter joined VBI in September of 2009.

article thumbnail

HHS review of a vaccine contract sparks worries about preparedness for a potential bird flu pandemic

STAT

In the spring of 2009, the first flu pandemic in four decades began. The world got lucky in 2009. Caused by an H1N1 virus that emerged from pigs, likely in Mexico, it spread quickly around the globe.

Immunity 340
article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths.

article thumbnail

GRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disorders

pharmaphorum

Nicole Raleigh 30 June, 2025 Rare diseases Bookmark this News Moderna shines spotlight on new flu vaccine data Moderna may be facing regulatory uncertainty in the US for its vaccine pipeline, but at least its clinical data is hitting the right notes. pharmaphorum – an EVERSANA company The rights of trademark owners are acknowledged.